Subject Index

A
Adolescence
Onset of schizophrenia in adolescence: An 11-year followup, 19:563
Precursors of affective vs. social deficits in adolescents at risk for schizophrenia, 19:563

Adoption studies
Genetic-epidemiologic schizophrenia perspective, 19:261

Affective deficits and social deficits
Distinguishing between, 18:59
Precursors of affective vs. social deficits in adolescents at risk for schizophrenia, 19:563

Age factors
Age of onset significance, 18:209
Alzheimer-type neuropathology in elderly schizophrenics, 19:805
Brain imaging in late-life schizophrenia and related psychoses, 19:773
Clinical characteristics of late-onset schizophrenia and delusional disorder, 19:701
Contagion in schizophrenia, 19:449, 19:455
Course of schizophrenia: Neuropsychological evidence for a static encephalopathy, 19:797
D_{2} dopamine receptor PET and structural MRI changes in late-onset schizophrenia, 19:783
Epidemiology of late-onset schizophrenia, 19:691
Extrapyramidal motor abnormalities associated with late-life psychosis, 19:747
Frontal leukotomy and aging in chronic schizophrenia, 19:723
Gender differences in tardive dyskinesia, 18:701
Hospitalization changes with passage of time, 18:229
Late-life schizophrenia: A clinical study, 19:709
Late-life schizophrenia: Editor's introduction, 19:687
Manifestations of schizophrenia in late life, 19:683
Onset of schizophrenia in adolescence: An 11-year followup, 19:831
Premorbid and onset features of first-episode schizophrenia, 18:373
Rehospitalization risk, 18:217
Sensory gating and inhibitory function in late-life schizophrenia, 19:733
Sensory impairment in late-life schizophrenia, 19:755
Treating late-life schizophrenia with neuroleptics, 19:817

Alzheimer's disease
Alzheimer-type neuropathology in elderly schizophrenics, 19:805
Extrapyramidal motor abnormalities associated with late-life psychosis, 19:747

Amphetamine psychosis. See Methamphetamine psychosis

Anhedonia
Anhedonia, attentional deviance, and psychopathology in the New York High-Risk Project, 19:141

Animal models
Chronic methamphetamine intoxication animal model, 18:67, 18:107
Hippocampal dysgenesis in mutant mouse and schizophrenic man, 19:21
31P Nuclear magnetic resonance spectroscopy, 19:35
Relapse of paranoid psychotic state in methamphetamine model, 18:115

Antidepressants
Eye tracking dysfunction and, 19:461

Antipsychotic drugs. See Neuroleptics

Association studies
Genetic-epidemiologic schizophrenia perspective, 19:261

**Attention dysfunctions**
Anhedonia, attentional deviance, and psychopathology in the New York High-Risk Project, 19:141
Information processing and attention dysfunctions, 19:233
Precursors of affective vs. social deficits in adolescents at risk for schizophrenia, 19:563
Schizotypal personality individuals, 18:717
Sensory gating and inhibitory function in late-life schizophrenia, 19:733

**Autobiographical accounts. See also Subjective experiences**
Brother’s view of brother’s illness, 18:155
Children of schizophrenics, 19:649
Inside view of illness, 18:333
Mother’s view of daughter’s illness, 19:853
Multiple-diagnosis illness, 18:725
Paranoia onset, 19:165
Treatment issues, 18:543

**Autoimmunity**
Infection and autoimmunity as etiologic factors, 19:355

**Behavior**
Affective deficits and social deficits, 18:59
Chronic methamphetamine intoxication animal model, 18:107
Cognitive-behavioral therapy, 18:27
Dopamine function and its role in cognitive deficits, 19:85
Frontal leukotomy and aging in chronic schizophrenia, 19:723
Information dysregulation and event-related potentials, 18:95
Neuroimaging in schizophrenia research, 19:337
Neuropsychological and eye movement abnormalities in first-episode and chronic schizophrenia, 18:283
Psychological distress determinants in relatives of people with chronic schizophrenia, 19:619
Sensory gating and inhibitory function in late-life schizophrenia, 19:733
Subjective response to neuroleptics, 19:609
Treating cognitive dysfunctions and behavioral deficits, 18:21

**Biological markers**
Japanese schizophrenia research history, 18:67
Psychobiology in first-episode schizophrenia at Hillside Hospital, 18:351

**Biological psychiatry**
Japanese schizophrenia research history, 18:67

**Body fluid measurements**
Homovanillic acid measurement in clinical research, 18:123

**Brain areas**
Anomalous lateral sulcus asymmetry and cognitive function, 18:257
Cingulate cortex neurobiological investigations, 19:537
Frontal, temporolimbic, and basal ganglia systems, 19:337
Frontal leukotomy and aging in chronic schizophrenia, 19:723

**Brain development**
Cerebral metabolism and structure abnormalities, 19:55
Cingulate cortex neurobiological investigations, 19:537
Contagion in schizophrenia, 19:449, 19:455
Hippocampal dysgenesis in mutant mouse and schizophrenic man, 19:21
Infection and autoimmunity as etiologic factors, 19:355
Neurodevelopmental approach to classification, 18:319

Neuropathology advances, 19:431
Parallel distributed processing and symptom emergence, 19:119

**Brain imaging**
Brain imaging in late-life schizophrenia and related psychoses, 19:773
Cerebral metabolism and structure abnormalities, 19:55
D₂ dopamine receptor PET and structural MRI changes in late-onset schizophrenia, 19:783
Neuroimaging in schizophrenia research, 19:337
3¹P Nuclear magnetic resonance spectroscopy, 19:35
Ventricle-to-brain ratio and symptoms at first-break onset, 18:427

**Brain morphology**
Alzheimer-type neuropathology in elderly schizophrenics, 19:805
Brain tissue acquisition issues, 18:149
Neuropathology advances, 19:431

**Brief Psychiatric Rating Scale**
Negative symptom assessment of chronic schizophrenia patients, 19:627

**Caregivers**
Psychological distress determinants in relatives of people with chronic schizophrenia, 19:619

**Central nervous system diseases**
Extrapyramidal motor abnormalities associated with late-life psychosis, 19:747
Genetic contribution studies, 18:159

**Classification**
Diagnosis and classification of schizophrenia, 19:199
First-episode studies reviewed, 18:491
Neurodevelopmental approach to classification, 18:319
Positive symptoms and diagnostic criteria, 18:551

Cognition
Anomalous lateral sulcus asymmetry and cognitive function, 18:257
Behavioral deficits and cognitive dysfunctions, 18:21
Cognitive-behavioral therapy, 18:27
Cognitive remediation, 18:15, 18:43, 18:51
Course of schizophrenia: Neuropsychological evidence for a static encephalopathy, 19:797
Dopamine function and its role in cognitive deficits, 19:85
Frontal leukotomy and aging in chronic schizophrenia, 19:723
Information dysregulation and event-related potentials, 18:95
Information processing and attention dysfunctions, 19:233
Intelligence deficits in first-episode schizophrenia, 18:437
Psychosocial treatment, 19:317
Reply to “Cognitive Therapy and Schizophrenia,” 18:37
Research design prerequisites for cognitive therapy, 18:39
Sensory gating and inhibitory function in late-life schizophrenia, 19:733
Symptom relation to cognitive deficits, 19:215

Computer simulation models
Dopamine function and its role in cognitive deficits, 19:85
Parallel distributed processing and symptom emergence, 19:119

Concordance rates
Genetic contribution may be overestimated, 18:159
Probandwise, pairwise rate use when assessing twin concordance, 18:171

Contagion
Critique of Crow and Done (1986), 19:449
Reply to Butler and Stieglitz, 19:455

Course and outcome. See First-episode psychosis; Long-term followup studies; Prospective studies; Statistical issues

Cultural factors
Clinical services research, 18:561
Gender differences in tardive dyskinesia, 18:701
Service systems research, 18:627

D
Delusions
Autobiographical account, 19:165
Clinical characteristics of late-onset schizophrenia and delusional disorder, 19:701
Phenomenological approach, 19:579
Relations of symptoms to cognitive deficits, 19:215

Demographic factors
Generalization of first-episode studies, 18:463
Late-life schizophrenia: A clinical study, 19:709
Service systems research, 18:627

Developmental Processes in Schizophrenic Disorders project, 18:387

Diagnosis
Alzheimer-type neuropathology in elderly schizophrenics, 19:805
Clinical services research, 18:561
Diagnosis and classification of schizophrenia, 19:199
First-episode studies reviewed, 18:491
Generalization of first-episode studies, 18:463
Late-life schizophrenia: A clinical study, 19:709
McLean First-Episode Psychosis Project, 18:273

Positive symptoms and diagnostic criteria, 18:551
Suffolk County Mental Health Project, 18:243

Diagnostic and Statistical Manual
Diagnosis and classification of schizophrenia, 19:199
Positive symptoms and diagnostic criteria, 18:551

Disability level among severely mentally ill
Research resources, 18:669
Service systems research, 18:627

Dopamine
Dopamine function and its role in cognitive deficits, 19:85
D2 dopamine receptor PET and structural MRI changes in late-onset schizophrenia, 19:783
Homovanillic acid measurement in clinical research, 18:123
Relapse of paranoid psychotic state in methamphetamine model, 18:115

Dosage considerations
Low-dose depot medication, 19:155
Psychopharmacologic treatment, 19:287

E
Early stages of psychosis. See First-episode psychosis

Economic factors
Cost considerations in rationing mental health care, 19:843
Reply to “Cognitive Therapy and Schizophrenia,” 18:37
Research resources, 18:669
Service systems research, 18:627

Electrodermal activity
Recent-onset schizophrenia symptoms and prognosis, 18:295

Environmental factors
Age of onset significance, 18:209
Contagion in schizophrenia, 19:449, 19:455
Developmental processes in schizophrenic disorders: Longi-
Seasonal studies of vulnerability and stress, 18:387
Infection and autoimmunity as etiologic factors, 19:355
Seasonality and stillbirths, 19:557

**Epidemiology**
Clinical services research, 18:561
Contagion in schizophrenia, 19:449, 19:455
Epidemiology of late-onset schizophrenia, 19:691
Genetic-epidemiologic schizophrenia perspective, 19:261
Japanese epidemiological studies, 18:75
Natural course of illness among first-admission patients, 18:185
Neuroleptic-induced tardive dyskinesia, 19:303
Suffolk County Mental Health Project, 18:243

**Etiology. See also Genetic factors**
Affective deficits and social deficits, 18:59
Age of onset significance, 18:209
Brain imaging in late-life schizophrenia and related psychoses, 19:773
Cerebral metabolism and structure abnormalities, 19:55
Contagion in schizophrenia, 19:449, 19:455
Diagnosis and classification of schizophrenia, 19:199
D₂ dopamine receptor PET and structural MRI changes in late-onset schizophrenia, 19:783
Hippocampal dysgenesis in mutant mouse and schizophrenic man, 19:21
Infection and autoimmunity as etiologic factors, 19:355
Neurochemistry and neuroendocrinology of schizophrenia, 19:371
Neurodevelopmental approach to classification, 18:319
Neuropathology advances, 19:431
Phenomenological approach to delusions, 19:579

Seasonality and stillbirths, 19:557
Sensory impairment in late-life schizophrenia, 19:755

**Event-related potentials**
Information dysregulation and, 18:95

**Excitatory amino acid receptors**
Involvement of excitatory amino acid systems in schizophrenia, 19:105

**Extrapyramidal symptoms. See also Tardive dyskinesia**
Extrapyramidal motor abnormalities associated with late-life psychosis, 19:747
Treating neuroleptic-nonresponsive patients, 18:515

**Eye movement studies**
Eye tracking dysfunction, 19:461
Japanese schizophrenia research, 18:67, 18:85
Neuropsychological and eye movement abnormalities in first-episode and chronic schizophrenia, 18:283

**F**

**Families**
Children of schizophrenia individuals, 19:649
Eye tracking dysfunction, 19:461
Genetic contribution studies, 18:159
Genetic-epidemiologic schizophrenia perspective, 19:261
Psychiatric rehabilitation role, 18:341
Psychological distress determinants in relatives of people with chronic schizophrenia, 19:619
Psychosocial treatment, 19:317
Service systems research, 18:627
Sibling perspectives on schizophrenia and the family, 19:637

**First-episode psychosis**
Age of onset significance, 18:209
Anomalous lateral sulcus asymmetry and cognitive function, 18:257
Developmental processes in schizophrenic disorders, 18:387
Editors' introduction, 18:177, 18:349
Electrodermal anomalies in recent-onset schizophrenia, 18:295
Epidemiology of psychosis, 18:243
Generalization of first-episode studies, 18:463
Intellectual deficits in first-episode schizophrenia, 18:437
Iowa prospective longitudinal study of recent-onset psychoses, 18:481
Long-term course of hospitalization, 18:217, 18:229
McLean First-Episode Psychosis Project, 18:273
Natural course of schizophrenia: Review of first-admission studies, 18:185
Neuropsychological and eye movement abnormalities in first-episode and chronic schizophrenia, 18:283
Phenomenology and functioning in, 18:449
Predominance of male research subjects, 18:471
Premorbid and onset features of first-episode schizophrenia, 18:373
Psychobiology in first-episode schizophrenia at Hillside Hospital, 18:351
Research report, 18:179
Review of first-episode studies: Criteria and characterization, 18:491
Ventricle-to-brain ratio and symptoms at onset, 18:427

**G**

**Gender differences**
Age of onset significance, 18:209
Anhedonia, attentional deviance, and psychopathology in the New York High-Risk Project,
Anomalous lateral sulcus asymmetry and cognitive function, 18:257
Epidemiology of late-onset schizophrenia, 19:691
Hospitalization changes with passage of time, 18:229
Late-life schizophrenia: A clinical study, 19:709
Predominance of male research subjects, 18:313, 18:471
Psychological distress determinants in relatives of people with chronic schizophrenia, 19:619
Rehospitalization risk, 18:217
Reply to “Sampling Biases in Studies of Gender and Schizophrenia,” 19:9
Sampling biases in studies of gender and schizophrenia, 19:1
Tardive dyskinesia gender differences, 18:701
Genetic factors
Age of onset significance, 18:209
Anhedonia, attentional deviance, and psychopathology in the New York High-Risk Project, 19:141
Cingulate cortex neurobiological investigations, 19:537
Contagion in schizophrenia, 19:449, 19:455
Eye tracking dysfunction, 19:461
Genetic-epidemiologic schizophrenia perspective, 19:261
Hippocampal dysgenesis in mutant mouse and schizophrenic man, 19:21
Precursors of affective vs. social deficits in adolescents at risk for schizophrenia, 19:563
Probandwise, pairwise rate use when assessing twin concordance, 18:171
Twin studies of schizophrenia, 18:159
Grants
Research resources, 18:669
Schizophrenia-related grants, fiscal year 1991, 19:171
Schizophrenia-related grants, fiscal year 1992, 19:651
Hallucinations
Clinical characteristics of late-onset schizophrenia and delusional disorder, 19:701
Relation of symptoms to cognitive deficits, 19:215
Homovanillic acid
Measurement in clinical research, 18:123
Hospitalization
Changes with passage of time, 18:229
Cost considerations in rationing mental health care, 19:843
McLean First-Episode Psychosis Project, 18:273
Rehospitalization risk, 18:217
Soviet visit to mental health and forensic facilities, 18:1, 18:7
Suffolk County Mental Health Project, 18:243
Housing for severely mentally ill persons
Service systems research, 18:627
Human resource development for mental health profession
Research resources, 18:669
Service systems research, 18:627
Immune response
Infection and autoimmunity as etiologic factors, 19:355
Infections. See also Viral infections
Infection and autoimmunity as etiologic factors, 19:355
Seasonality and stillbirths, 19:557
Information dysregulation. See Cognition
Information processing dysfunctions. See Cognition
Insurance
Service systems research, 18:627
Integrated Psychological Therapy, 18:21, 18:27, 18:37
Intellectual deficits. See Cognition
Iowa prospective longitudinal study of recent-onset psychoses, 18:471
Japanese schizophrenia research
Chronic methamphetamine intoxication animal model, 18:107
Editor’s introduction, 18:65
Epidemiological studies, 18:75
Exploratory eye movements and neuropsychological tests, 18:85
History, 18:67
Information dysregulation and event-related potentials, 18:95
Paranoid psychotic state relapse in methamphetamine model, 18:115
Late-life schizophrenia. See Age factors
Legal issues
Brain tissue acquisition issues, 18:149
Service systems research, 18:627
Soviet visit to mental health and forensic facilities, 18:1, 18:7
Linkage studies
Genetic-epidemiologic schizophrenia perspective, 19:261
Lithium
Eye tracking dysfunction and, 19:461
Long-term followup studies
Brain imaging in late-life schizophrenia and related psychoses, 19:773
Clinical characteristics of late-onset schizophrenia and delusional disorder, 19:701
Cost considerations in rationing mental health care, 19:843
Course of schizophrenia: Neuropsychological evidence for a static encephalopathy, 19:797
Developmental processes in schizophrenia disorders, 18:387

D₂ dopamine receptor PET and structural MRI changes in late-onset schizophrenia, 19:783

Electrodermal anomalies in recent-onset schizophrenia, 18:295

Frontal leukotomy and aging in chronic schizophrenia, 19:723

Hospitalization changes with passage of time, 18:229

Iowa prospective longitudinal study of recent-onset psychoses, 18:481

Late-life schizophrenia: Editor’s introduction, 19:687

Manifestations of schizophrenia in late life, 19:683

McLean First-Episode Psychosis Project, 18:273

Natural course of illness among first-admission patients, 18:185

Neuroleptic-induced tardive dyskinesia, 19:303

New York High-Risk Project, 19:141

Onset of schizophrenia in adolescence: An 11-year followup, 19:831

Precursors of affective vs. social deficits in adolescents at risk for schizophrenia, 19:563

Psychobiology in first-episode schizophrenia at Hillside Hospital, 18:351

Rehospitalization risk, 18:217

Subtype progression and pathophysiologic deterioration in early schizophrenia, 19:71

Suffolk County Mental Health Project, 18:243

Treating late-life schizophrenia with neuroleptics, 19:817

Marital status
Rehospitalization risk, 18:217

McLean First-Episode Psychosis Project, 18:273

Medication effects
Eye tracking dysfunction, 19:461

Low-dose depot medication in schizophrenia, 19:155

Methamphetamine psychosis
Chronic methamphetamine intoxication animal model, 18:107

Japanese schizophrenia research history, 18:67

Relapse of paranoid psychotic state in methamphetamine model, 18:115

Minor physical anomalies
Minor physical anomalies in schizophrenia and mood disorders, 19:551

Mood disorder
Minor physical anomalies in schizophrenia and mood disorders, 19:551

N

Nagasaki Incidence Rate Study, 18:65, 18:75

Neurodynamics
Cerebral metabolism and structure abnormalities, 19:55

Dopamine function and its role in cognitive deficits, 19:85

Editors’ introduction, 19:15

Excitatory amino acid receptors in schizophrenia, 19:105

Hippocampal dysgenesis in mutant mouse and schizophrenic man, 19:21

³¹P Nuclear magnetic resonance spectroscopy, 19:35

Parallel distributed processing and symptom emergence, 19:119

Subtype progression and pathophysiologic deterioration in early schizophrenia, 19:71

Neuroendocrinology
Neurochemistry and neuroendocrinology of schizophrenia, 19:371

Neuroleptics
Developmental processes in schizophrenic disorders, 18:387

Extrapyramidal motor abnormalities associated with late-life psychosis, 19:747

Eye-tracking dysfunction and, 19:461

Gender differences in tardive dyskinesia, 18:701

Information processing and attention dysfunctions, 19:233

Low-dose depot medication, 19:155

Psychopharmacologic treatment, 19:287

Psychosocial treatment, 19:317

Subjective response to neuroleptics, 19:609

Treating late-life schizophrenia, 19:817

Treating neuroleptic-nonresponsive patients, 18:515

Neuromotor dysfunction
Precursors of affective vs. social...
deficits in adolescents at risk for schizophrenia, 19:563

Neuropathology
Advances in, 19:431
Alzheimer-type neuropathology in elderly schizophrenia patients, 19:805

Neuropsychology
Cognitive remediation, 18:15, 18:51
Course of schizophrenia: Neuropsychological evidence for a static encephalopathy, 19:797
Exploratory eye movements and neuropsychological tests, 18:85
Neuropsychological and eye movement abnormalities in first-episode and chronic schizophrenia, 18:283
Relation of symptoms to cognitive deficits, 19:215

Neurotransmitters. See also Neurodynamics
Cingulate cortex neurobiological investigations, 19:537
Excitatory amino acid receptors, 19:105
Homovanillic acid measurement in clinical research, 18:123
Neurochemistry and neuroendocrinology of schizophrenia, 19:371

New York High-Risk Project, 19:141, 19:563

31P Nuclear magnetic resonance spectroscopy
Neurodevelopment studies, 19:35

Onset of psychosis. See First-episode psychosis
outcome. See Long-term followup studies; National Plan for Schizophrenia Research, Clinical services research

Pathophysiology
Diagnosis and classification of schizophrenia, 19:199
Eye tracking dysfunction, 19:461
Neurochemistry and neuroendocrinology of schizophrenia, 19:371
Neuroleptic-induced tardive dyskinesia, 19:303
Subtype progression and pathophysiologic deterioration in early schizophrenia, 19:71

Patient rights
Soviet visit to mental health and forensic facilities, 18:1, 18:7

Personnel strategies for mental health profession
Research resources, 18:669
Service systems research, 18:627

Phenomenology
Phenomenological approach to delusions, 19:579
Phenomenology and functioning in first-episode schizophrenia, 18:449
Subtype progression and pathophysiologic deterioration in early schizophrenia, 19:71

Phospholipids
Neurochemistry and neuroendocrinology of schizophrenia, 19:371

Physical anomalies
Mood disorders and minor physical anomalies in schizophrenia, 19:551

Positive symptoms
Diagnostic criteria and, 18:551

Positron emission tomography
D2 dopamine receptor PET and structural MRI changes in late-onset schizophrenia, 19:783

Prognosis. See Long-term followup studies

Prospective studies
Iowa prospective longitudinal study of recent-onset psychoses, 18:481
Natural course of illness among first-admission patients, 18:185

Neuroleptic-induced tardive dyskinesia, 19:303
Psychobiology in first-episode schizophrenia at Hillside Hospital, 18:351
Treating late-life schizophrenia with neuroleptics, 19:817

Psychobiology
Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital, 18:351

Psychological deficits. See Cognition

Psychological distress
Determinants of in relatives of people with chronic schizophrenia, 19:619

Psychosocial functioning
Psychosocial treatment for schizophrenia, 19:317
Subjective experience and, 19:599

Reaction time studies
Schizotypal personality individuals, 18:717

Rehabilitation
Clinical services research, 18:561
Cost considerations in rationing mental health care, 19:843
Research resources, 18:669
Service systems research, 18:627

Relapse of paranoid psychotic state
Methamphetamine model of schizophrenia, 18:115

Research design and methodology. See also Japanese schizophrenia research
Alzheimer-type neuropathology in elderly schizophrenics, 19:805
Brain imaging in late-life schizophrenia and related psychoses, 19:773
Brain tissue acquisition issues, 18:149

Chronic methamphetamine intoxic-
SCHIZOPHRENIA BULLETIN

ication animal model, 18:67, 18:107
Clinical characteristics of late-onset schizophrenia and delusional disorder, 19:701
Clinical services research, 18:561
Cognitive therapy research design prerequisites, 18:39
Concordance rates for twin studies, 18:159, 18:171
Course of schizophrenia: Neurophysiological evidence for a static encephalopathy, 19:797
Diagnosis and classification of schizophrenia, 19:199
Dopamine function and its role in cognitive deficits, 19:85
D2 dopamine receptor PET and structural MRI changes in late-onset schizophrenia, 19:783
Electrodermal anomalies in recent-onset schizophrenia, 18:295
Epidemiology of late-onset schizophrenia, 19:691
Extrapyramidal motor abnormalities associated with late-life psychosis, 19:747
Eye tracking dysfunction literature review, 19:461
First-episode psychosis, 18:179, 18:491
Frontal leukotomy and aging in chronic schizophrenia, 19:723
Generalization of first-episode studies, 18:463
Genetic-epidemiologic schizophrenia perspective, 19:261
Homovanillic acid measurement in clinical research, 18:123
Information processing/attention research, 19:233
Iowa prospective longitudinal study of recent-onset psychoses, 18:481
Late-life schizophrenia: A clinical study, 19:709
McLean First-Episode Psychosis Project, 18:273
Neurodynamics and research, 19:15
Neuroimaging in schizophrenia research, 19:337
Neuroleptic-induced tardive dyskinesia, 19:303
31P Nuclear magnetic resonance spectroscopy, 19:35
Onset of schizophrenia in adolescence: An 11-year followup, 19:831
Parallel distributed processing and symptom emergence, 19:119
Phenomenological approach to delusions, 19:579
Predominance of male research subjects, 18:313, 18:471
Probandwise, pairwise rate use when assessing twin concordance, 18:171
Psychobiology in first-episode schizophrenia at Hillside Hospital, 18:351
Relapse of paranoid psychotic state in methamphetamine model, 18:115
Reply to “Sampling biases in studies of gender and schizophrenia,” 19:9
Research resources, 18:669
Sampling biases in studies of gender and schizophrenia, 19:1
Sensory gating and inhibitory function in late-life schizophrenia, 19:733
Sensory impairment in late-life schizophrenia, 19:755
Service systems research, 18:627
Subjective response to neuroleptics, 19:609
Suffolk County Mental Health Project, 18:243
Treating late-life schizophrenia with neuroleptics, 19:817
S
Scales
Anhedonia, attentional deviance, and psychopathology in the New York High-Risk Project, 19:141
Negative Symptom Assessment scale, 19:627
Waldrop Physical Anomaly Scale, 19:551
Schizotypal personality disorder
Disorder of attention, 18:717
Eye tracking dysfunction, 19:461
Season of birth
Seasonality of schizophrenia and stillbirths, 19:557
Sensory impairment
Sensory impairment in late-life schizophrenia, 19:755
Siblings
Sibling perspectives on schizophrenia and the family, 19:637
Social functioning
Affective deficits and social deficits, 18:59
Cognitive-behavioral therapy, 18:27
Cognitive rehabilitation critique and suggestions, 18:43
Precursors of affective vs. social deficits in adolescents at risk for schizophrenia, 19:563
Psychosocial functioning and subjective experience, 19:599
Psychosocial treatment, 19:317
Treating cognitive dysfunctions and behavioral deficits, 18:21
Socioeconomic factors
Clinical services research, 18:561
Service systems research, 18:627
Soviet delegation professional visit, 18:1, 18:7
Statistical issues
Iowa prospective longitudinal study of recent-onset psychoses, 18:481
Natural course of illness among first-admission patients, 18:185
Stillbirths
Seasonality and stillbirths, 19:557
Stress factors. See Environmental factors
Subjective experiences
Psychosocial functioning and subjective experience, 19:599
Sibling perspectives on schizophrenia and the family, 19:637
Subjective response to neuroleptics, 19:609

Substance abuse comorbidity
Autobiographical account, 18:725
Psychosocial treatment, 19:317
Suffolk County Mental Health Project, 18:243

Substance-induced psychoses. See Methamphetamine psychosis

Suffolk County Mental Health Project, 18:243

Symptoms
Affective deficits and social deficits, 18:59, 19:563
Anhedonia, attentional deviance, and psychopathology in the New York High-Risk Project, 19:141
Clinical characteristics of late-onset schizophrenia and delusional disorder, 19:701
Clinical services research, 18:561
Developmental processes in schizophrenic disorders, 18:387
Diagnosis and classification of schizophrenia, 19:199
Electrodermal anomalies in recent-onset schizophrenia, 18:295
Exploratory eye movements and neuropsychological tests, 18:85
Extrapyramidal motor abnormalities associated with late-life psychosis, 19:747
Intellectual deficits in first-episode schizophrenia, 18:437
Late-life schizophrenia: A clinical study, 19:709
Manifestations of schizophrenia in late life, 19:683
Negative symptom assessment of chronic schizophrenia patients, 19:627
Neuroimaging in schizophrenia research, 19:337
Onset of schizophrenia in adolescence: An 11-year followup, 19:831
Parallel distributed processing and symptom emergence, 19:119
Phenomenology and functioning in first-episode schizophrenia, 18:449
Positive symptoms and diagnostic criteria, 18:551
Premorbid and onset features of first-episode schizophrenia, 18:373
Relapse of paranoid psychotic state in methamphetamine model, 18:115
Relation of symptoms to cognitive deficits, 19:215
Subtype progression and pathophysiological deterioration in early schizophrenia, 19:71
Treating late-life schizophrenia with neuroleptics, 19:817
Treating neuroleptic-nonresponsive patients, 18:515
Ventricle-to-brain ratio and symptoms at onset, 18:427

Tardive dyskinesia
Gender differences, 18:701
Minor physical anomalies in schizophrenia and mood disorders, 19:551
Prospective study, 19:303
Twin studies
Twin studies
Concordance rates for, 18:159
Genetic-epidemiologic schizophrenia perspective, 19:261
Probandwise, pairwise concordance rate use, 18:171

Ventricle-to-brain ratio
Ventricle-to-brain ratio and symptoms at first-break onset, 18:427

Viral infections
Contagion in schizophrenia, 19:449, 19:455
Hippocampal dysgenesis in mu-
Vulnerability factors
Developmental processes in schizophrenic disorders, 18:387

Phenomenological approach to delusions, 19:579

Zygosity determination. See Twin studies

Waldrop Physical Anomaly Scale, 19:551

Announcement

The Fourth International Conference entitled Innovations in Community Psychiatry will be held at the University of York, York, United Kingdom, March 23-25, 1994. The scientific program will feature plenary sessions with leading international speakers, symposia and panel discussions, workshops, poster presentations, free papers, original research papers, and film and video presentations.

For further information, please contact:
International Institute of Community Psychiatry
P.O. Box B135
Huddersfield HD1 1YG
United Kingdom
Telephone: 0484 532102
Fax: 0484 425699
In December 1969, the first issue of the *Schizophrenia Bulletin* was issued on an experimental basis. Its appearance was followed over the next 4 years by 10 additional experimental issues. On September 25, 1974, permission was granted by the Office of Management and Budget for the *Bulletin* to be established as a regular quarterly publication. The Secretary of Health and Human Services has determined that the publication of this periodical is necessary in the transaction of the public business required by law of this Department. Use of funds for printing this periodical has been approved by the Director of the Office of Management and Budget through September 30, 1994.

The subscription price, covering four issues per year, is $17.00 domestic and $21.25 foreign. The single copy price is $9.00 domestic and $11.25 foreign. This price was in effect at time of printing. Prices are subject to change. We urge those intending to subscribe or renew to complete the subscription order form (see below) as soon as possible. Your check or money order should be made payable and mailed, together with your order form, to the Superintendent of Documents, New Orders, P.O. Box 371954, Pittsburgh, PA 15250-7954.

Notices of change of address and complaints about nonreceipt of issues should be sent to the Superintendent of Documents, Mail List Branch, Mail Stop: SSOM, Washington, DC 20402-9375, and should include the old address, preferably a mailing label, as well as the new address.
Instructions to Authors

Submissions to the Schizophrenia Bulletin should be sent to:

David Shore, M.D.
Editor-in-Chief
Schizophrenia Bulletin
National Institute of Mental Health
5600 Fishers Lane, Rm. 18C-06
Rockville, MD 20857

The editors will consider critical reviews of the literature, articles reporting original observations in laboratory or clinical research, short reports of preliminary or negative research results, first person accounts by patients or family members, and letters to the editor. News items describing research and training programs or reporting professional activities in schizophrenia are also welcome. Photographs of art done by current or former mental hospital patients may be submitted for possible reproduction on the cover of the Bulletin; the artist must be willing to grant permission for publication of his or her work, but his or her anonymity will be preserved if he or she so wishes.

All materials published in the Schizophrenia Bulletin are in the public domain unless otherwise noted.

Preparation of Manuscript

A detailed set of instructions for manuscript preparation is available from the Research Projects and Publications Branch (see address above).

Text and Tables: Type the manuscript (double space) on one side of the page, and submit in quadruplicate—one copy an original and the other three photocopies. Present each table on a separate sheet. Note the table number in the text immediately after the paragraph in which it is described.

Abstract: Provide a brief abstract of the manuscript. The abstract should not exceed 175 words in length.

Illustrations: Submit one copy of each chart, graph, or other illustration in reproducible form (either original drawings in black india ink or glossy prints). Refer to all illustrative materials as text figures. Type the figure number and legend for each on a separate sheet.

References: Include a list of all articles and books cited in the text. Arrange alphabetically by major author. When referring to these sources in the text, place the authors’ names and the date of publication in parentheses immediately after the idea referenced. If more than one source is cited, list in chronological order by date of publication. (If authors’ names are used in the same sentence, place only the date of publication in parentheses.) Provide page numbers for all quotes. Spell out all journal titles. Bibliographic style should follow that used in articles in this issue.

Footnotes: Use footnotes to clarify textual material, and indicate them by superior figures in the text. Insert footnotes as separate paragraphs immediately following the paragraphs in which they are mentioned.

Author Identification: Include your own and each author’s official title and academic degrees. Specify the address to which reprints should be sent.
In This Issue

Detailed Table of Contents ........................................... i
At Issue .......................................................... 683
Late-Life Schizophrenia: Editor's Introduction—
D.V. Jeste .................................................. 687
The Epidemiology of Late-Onset Schizophrenia—
D.J. Castle and R.M. Murray .................................. 691
Clinical Characteristics of Late-Onset Schizophrenia
and Delusional Disorder—R. Yassa and
B. Suranyi-Cadotte ................................................ 701
Schizophrenia in Late Life—B.H. Mulsant et al. .......... 709
Leukotomy and Aging in Chronic Schizophrenia—
P.D. Harvey et al. .................................................. 723
Sensory Gating and Inhibitory Function in
Late-Life Schizophrenia—J.M. McDowd et al. .......... 733
Extrapyramidal Motor Abnormalities Associated With
Late-Life Psychosis—M.P. Caligiuri et al. ................. 747
Sensory Impairment in Late-Life Schizophrenia—
S. Prager and D.V. Jeste ......................................... 755
Brain Imaging in Late-Life Schizophrenia and
Related Psychoses—I.M. Lesser et al. ..................... 773
Quantitative D₂ Dopamine Receptor PET and Structural
MRI Changes in Late-Onset Schizophrenia—
G.D. Pearlson et al. ............................................ 783
Course of Schizophrenia—T.E. Goldberg et al. ........... 797
Alzheimer-Type Neuropathology in Elderly Schizophrenia
Patients—I. Prohovnik et al. .................................. 805
Treatment of Late-Life Schizophrenia With
Neuroleptics—D.V. Jeste et al. .............................. 817
Schizophrenia With Onset in Adolescence—M. Krausz
and T. Müller-Thomsen ........................................ 831
Who Should Receive High-Cost Mental Health Treatment and
for How Long?—R. Rosenheck et al. ....................... 843
First Person Account: How Do I Let Go?—W. Winship .... 853